Should inverse agonists be defined by pharmacological mechanism or clinical effect?

CNS Spectr. 2019 Aug;24(4):349-351. doi: 10.1017/S1092852918001761. Epub 2019 Mar 20.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacology*
  • Antiparkinson Agents / therapeutic use
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / pharmacology*
  • Antipsychotic Agents / therapeutic use
  • Humans
  • Piperidines / adverse effects
  • Piperidines / pharmacology*
  • Piperidines / therapeutic use
  • Urea / adverse effects
  • Urea / analogs & derivatives*
  • Urea / pharmacology
  • Urea / therapeutic use

Substances

  • Antiparkinson Agents
  • Antipsychotic Agents
  • Piperidines
  • Urea
  • pimavanserin